Fernández-Prendes Carla, Castro-Castro Maria-José, Jiménez-Añón Laura, Morales-Indiano Cristian, Martínez-Bujidos María
Laboratory Medicine Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Commission on Lipoprotein and Vascular Diseases, Sociedad Española de Química Clínica.
EJIFCC. 2023 Apr 18;34(1):27-41. eCollection 2023 Apr.
Manufacturers evaluate lipemia-induced interference using Intralipid, but it does not contain all lipoprotein types. The aim of this study was to evaluate lipemiainduced interference in biochemical parameters from endogenous lipemic samples and SMOFlipid supplemented samples, in order to assess if SMOFlipid can be used in lipemic interference studies.
Serum pools were supplemented with SMOFlipid to achieve 800 mg/dL and 1500 mg/dL triglyceride concentration, and analyzed for 25 biochemical parameters both before and after the supplementation. In another independent phase, lipemic serum pools were prepared choosing patient samples of 800 mg/dL and 1500 mg/dL triglyceride concentration. These lipemic serum pools were ultracentrifugated in order to remove lipids. Biochemical parameters were analyzed before and after ultracentrifugation. The bias between SMOFlipid-supplemented samples and endogenous lipemic samples were compared. The bias between the lipemic and non-lipemic samples were compared with the reference change value.
At 800 mg/dL triglyceride concentration, we found that total protein and transferrin had been affected only in endogenous lipemic serum samples. Magnesium and creatinine had been affected only in SMOFlipid-supplemented samples. At 1500 mg/dL triglyceride concentration, we found that total protein, amylase, ferritin and glucose had lipemic interference only in endogenous lipemic samples, and chloride only in SMOFlipid-supplemented samples.
The use of SMOFlipid-supplemented samples does not provide suitable data to estimate lipemia-induced interference. Thus, interference studies should be performed using a wide variety of lipemic patient samples that represent the heterogeneity of the lipoprotein particles size.
制造商使用英脱利匹特评估脂血引起的干扰,但它并不包含所有脂蛋白类型。本研究的目的是评估内源性脂血样本和补充了SMOFlipid的样本中脂血对生化参数的干扰,以评估SMOFlipid是否可用于脂血干扰研究。
向血清混合液中补充SMOFlipid,使甘油三酯浓度达到800mg/dL和1500mg/dL,并在补充前后分析25项生化参数。在另一个独立阶段,选择甘油三酯浓度为800mg/dL和1500mg/dL的患者样本制备脂血血清混合液。对这些脂血血清混合液进行超速离心以去除脂质。在超速离心前后分析生化参数。比较补充SMOFlipid的样本与内源性脂血样本之间的偏差。将脂血样本与非脂血样本之间的偏差与参考变化值进行比较。
在甘油三酯浓度为800mg/dL时,我们发现总蛋白和转铁蛋白仅在内源性脂血血清样本中受到影响。镁和肌酐仅在补充了SMOFlipid的样本中受到影响。在甘油三酯浓度为1500mg/dL时,我们发现总蛋白、淀粉酶、铁蛋白和葡萄糖仅在内源性脂血样本中存在脂血干扰,而氯仅在补充了SMOFlipid的样本中存在干扰。
使用补充了SMOFlipid的样本无法提供合适的数据来估计脂血引起的干扰。因此,干扰研究应使用代表脂蛋白颗粒大小异质性的多种脂血患者样本进行。